Inhibition of lymphangiogenic factor VEGF-C expression and production by the histone deacetylase inhibitor suberoylanilide hydroxamic acid in breast cancer cells

By    

Oncology Reports, Vol. 29, Iss. 3, 2013-01 ,pp. : 1238-1244

Spandidos Publications

Access to resources Recommend Favorite

Continuous intracranial administration of suberoylanilide hydroxamic acid (SAHA) inhibits tumor growth in an orthotopic glioma model

By Ugur Hasan   Ramakrishna Naren   Bello Lorenzo   Menon Lata   Kim Seung-Ki   Black Peter   Carroll Rona  

Journal of Neuro-Oncology, Vol. 83, Iss. 3, 2007-07 ,pp. : 267-275

Springer Publishing Company

Access to resources Recommend Favorite

Suberoylanilide hydroxamic acid-induced HeLa cell death is closely correlated with oxidative stress and thioredoxin 1 levels

By    

International Journal of Oncology, Vol. 44, Iss. 5, 2014-01 ,pp. : 1745-1755

Spandidos Publications

Access to resources Recommend Favorite

Suberoylanilide hydroxamic acid enhances the antitumor activity of oxaliplatin by reversing the oxaliplatininduced Src activation in gastric cancer cells

By                

Molecular Medicine Reports, Vol. 10, Iss. 5, 2014-01 ,pp. : 2729-2735

Spandidos Publications

Access to resources Recommend Favorite

The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer

By Shi Yi-kang   Li Zhong-hua   Han Xi-qian   Yi Ji-hu   Wang Zhen-hua   Hou Jing-li   Feng Cong-ran   Fang Qing-hong   Wang Hui-hui   Zhang Peng-fei   Wang Feng-shan   Shen Jie   Wang Peng  

Cancer Chemotherapy and Pharmacology, Vol. 66, Iss. 6, 2010-11 ,pp. : 1131-1140

Springer Publishing Company

Access to resources Recommend Favorite